News
ASMB
20.63
+2.23%
0.45
Assembly Biosciences, Inc. Reports Third Quarter 2026 Financial Results and Recent Updates
NASDAQ · 5h ago
Assembly Biosciences (ASMB) Reports Q3 Loss, Lags Revenue Estimates
NASDAQ · 22h ago
Assembly Biosciences reports Q3 EPS (93c), consensus (49c)
TipRanks · 22h ago
Assembly Biosciences GAAP EPS of -$0.93 misses by $0.48, revenue of $2.96M misses by $4.3M
Seeking Alpha · 22h ago
Press Release: Assembly Biosciences Reports Third -2-
Dow Jones · 22h ago
*Assembly Biosciences 3Q Loss/Shr 93c >ASMB
Dow Jones · 22h ago
Press Release: Assembly Biosciences Reports Third Quarter 2026 Financial Results and Recent Updates
Dow Jones · 22h ago
*Assembly Biosciences 3Q Loss $20.3M >ASMB
Dow Jones · 22h ago
Assembly Biosciences: Q3 Earnings Snapshot
Barchart · 1d ago
Assembly Biosciences (ASMB) Gets a Buy from H.C. Wainwright
TipRanks · 1d ago
Assembly Biosciences Repeat Insider Selling Not A Positive Indicator
Simply Wall St · 3d ago
Weekly Report: what happened at ASMB last week (1102-1106)?
Weekly Report · 4d ago
U.S. Earnings Preview: After Market Close Nov. 6
Dow Jones · 6d ago
Assembly Biosciences Is Maintained at Buy by UBS
Dow Jones · 11/03 16:25
Assembly Biosciences Price Target Cut to $48.00/Share From $52.00 by UBS
Dow Jones · 11/03 16:25
UBS Maintains Buy on Assembly Biosciences, Lowers Price Target to $48
Benzinga · 11/03 16:15
H.C. Wainwright Sticks to Their Buy Rating for Assembly Biosciences (ASMB)
TipRanks · 11/03 12:58
Assembly Biosciences price target lowered to $48 from $52 at UBS
TipRanks · 11/03 12:45
Weekly Report: what happened at ASMB last week (1026-1030)?
Weekly Report · 11/02 09:20
Assembly Biosciences doses first two participants in ABI-6250 Phase 2 study
TipRanks · 10/29 20:55
More
Webull provides a variety of real-time ASMB stock news. You can receive the latest news about Assembly Bioscie through multiple platforms. This information may help you make smarter investment decisions.
About ASMB
Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small-molecule therapeutics designed to change the path of serious viral diseases and improve the lives of patients worldwide. Its pipeline includes multiple clinical-stage investigational therapies, including two helicase-primase inhibitors (HPI) targeting recurrent genital herpes; an orally bioavailable hepatitis delta virus (HDV) entry inhibitor, and a potent next-generation capsid assembly modulator (CAM) designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. Its pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) targeting transplant-related herpesviruses, which is undergoing studies to enable a regulatory filing, and it also has additional research programs against multiple antiviral targets. It is advancing two investigational long-acting HPI candidates, ABI-5366 (5366) and (2) ABI-1179 (1179).